<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Nov. 16, 2018 (HealthDay News) — Use of sodium glucose cotransporter 2 (SGLT2) inhibitors is associated with an increased risk for lower-limb amputation and diabetic ketoacidosis compared with use of glucagon-like peptide 1 (GLP1) receptor agonists, according to a study published online Nov. 14 in The BMJ<\/i>.<\/p>\n
Peter Ueda, M.D., Ph.D., from Karolinska University Hospital in Stockholm, and colleagues examined the correlation between SGLT2 inhibitors and serious adverse events of current concern in a register-based cohort study. Data were included for a propensity score-matched cohort of 17,213 new users of SGLT2 inhibitors and 17,213 new users of GLP1 receptor agonists.<\/p>\n
The researchers found that compared with GLP1 receptor agonists, use of SGLT2 inhibitors correlated with an increased risk for lower-limb amputation (incidence rate ratio, 2.7 versus 1.1 events per 1,000 person-years; hazard ratio [HR], 2.32; 95 percent confidence interval [CI], 1.37 to 3.91) and diabetic ketoacidosis (1.3 versus 0.6; HR, 2.14; 95 percent CI, 1.01 to 4.52). SGLT2 use was not associated with increased risks for bone fracture (15.4 versus 13.9; HR, 1.11; 95 percent CI, 0.93 to 1.33), acute kidney injury (2.3 versus 3.2; HR, 0.69; 95 percent CI, 0.45 to 1.05), serious urinary tract infection (5.4 versus 6.0; HR, 0.89; 95 percent CI, 0.67 to 1.19), venous thromboembolism (4.2 versus 4.1; HR, 0.99; 95 percent CI, 0.71 to 1.38), or acute pancreatitis (1.3 versus 1.2; HR, 1.16; 95 percent CI, 0.64 to 2.12).<\/p>\n
“The findings should be interpreted in the context of limitations of observational studies and the uncertainty of the effect estimates,” the authors write.<\/p>\n
Several authors disclosed financial ties to the pharmaceutical industry.<\/p>\n